Overview

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled trial assessing Losartan in reducing radiation induced fibrosis in breast cancer patients undergoing standard of care radiation therapy after surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Shaw Cancer Center
Collaborator:
Steadman Philippon Research Institute
Treatments:
Losartan